A Mab A Case Study In Bioprocess Development -

Case Study: Development of a Manufacturing Process for a Novel IgG1 Monoclonal Antibody (mAb-X)

1. Background & Target Product Profile (TPP)

Molecule: Humanized IgG1 mAb targeting a cancer antigen. Indication: Solid tumors. Target Dose: 500 mg per patient, every 3 weeks. Annual Demand: 50 kg (clinical → early commercial). Critical Quality Attributes (CQAs):

• Log Reduction Value (LRV) for XMuLV: 5.8 logs (Target >4).
• Risk: Initially, aggregation spiked to 12% after neutralization. This was resolved by titrating back to pH 5.5 using Tris-base (slow, linear gradient) rather than a bolus addition of NaOH.

The cell line development process involved several rounds of cloning and screening to identify a cell line with the desired characteristics, including: A Mab A Case Study In Bioprocess Development

Part 6: Scale-Up and Tech Transfer – 2,000L to 10,000L

The final scale-up from pilot (200L) to commercial (2,000L) was smooth, but transferring to an external CMO at 10,000L revealed surprises: Case Study: Development of a Manufacturing Process for

• High cell density (>10^6 cells/mL)
• High productivity (>15 pg/cell/day)
• Low levels of lactate and ammonia (<10 mM)

Enhanced Product Understanding: Identifying which molecular attributes impact safety and efficacy. Log Reduction Value (LRV) for XMuLV: 5

16. Conclusions and Recommendations

• Integrate molecule, cell line, upstream, downstream, and analytics decisions early.
• Prioritize CQAs with clear control strategies and use QbD/DoE to define robust operating ranges.
• Consider economic drivers (titer, resin use, facility strategy) when designing processes.
• Validate viral and impurity clearance rigorously; prepare regulatory CMC with comparability plans for future changes.
• Explore continuous processing and digital tools to improve efficiency and reduce cost of goods.

Conclusion: The Future of mAb Bioprocessing

A Mab reached the clinic in 28 months from transfection – 6 months ahead of schedule. Today, it’s a blockbuster therapy. But the bioprocess continues to evolve. The team is now implementing continuous bioprocessing (perfused N-1 and connected capture) to boost productivity to 15 g/L and reduce COGS by 40%.

5. Harvest and Primary Recovery

• Cell removal: depth filtration, centrifugation.
• Clarification strategies: single-step depth filtration vs multi-stage (centrifuge + depth filter) for high-density cultures; pre-coat filters to prevent fouling.
• Flocculation agents (polymers) when needed; impacts on downstream cleaning and analytical detection.